Patents by Inventor Gengfu XIAO

Gengfu XIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11919923
    Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: March 5, 2024
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Science, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Vigonvita Life Sciences Co., Ltd.
    Inventors: Yuanchao Xie, Gengfu Xiao, Yang He, Leike Zhang, Haji Akber Aisa, Hualiang Jiang, Jingshan Shen
  • Publication number: 20230312584
    Abstract: A salt of nucleoside analog, and crystal form, pharmaceutical composition and use thereof. The salt of nucleoside analog has a structure shown in formula I, wherein X is hydrogen or deuterium; Y is an acid, n is 0.5 to 2, or n is 1. When X is hydrogen or deuterium, Y is hydrogen bromide, and n is 1, the salt of the nucleoside analog exists in the form of a crystal with crystal form I or crystal form A or exists in an amorphous form.
    Type: Application
    Filed: October 21, 2021
    Publication date: October 5, 2023
    Applicants: VIGONVITA LIFE SCIENCES CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES
    Inventors: Jingshan SHEN, Yuanchao XIE, Leike ZHANG, Gengfu XIAO, Zhen WANG, Hualiang JIANG, Huaqiang XU, Tianwen HU, Guanghui TIAN
  • Publication number: 20230219993
    Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 13, 2023
    Inventors: Yuanchao XIE, Gengfu XIAO, Yang HE, Leike ZHANG, Heji Akber AISA, Hualiang JIANG, Jingshan SHEN
  • Publication number: 20230218606
    Abstract: Disclosed are hydroxychloroquine or chloroquine, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound, and the use thereof in the treatment of diseases or infections caused by SARS-CoV-2.
    Type: Application
    Filed: June 2, 2020
    Publication date: July 13, 2023
    Inventors: Wu Zhong, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Ruiyuan Cao, Wei Li, Shiyong Fan, Xinbo Zhou, Song Li
  • Publication number: 20230210807
    Abstract: Disclosed are the use of a benzoate compound as shown in formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof and/or a solvate thereof or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound in the prevention and treatment of SARS-CoV-2 infections.
    Type: Application
    Filed: July 15, 2020
    Publication date: July 6, 2023
    Inventors: Wu ZHONG, Ruiyuan CAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Wei LI, Yuexiang LI, Lei ZHAO, Shiyong FAN, Song LI
  • Publication number: 20230138310
    Abstract: Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavirus 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavirus infection 2019.
    Type: Application
    Filed: March 26, 2020
    Publication date: May 4, 2023
    Inventors: Hong LIU, Jian LI, Wenhao DAI, Jingjing PENG, Xiong XIE, Shulei HU, Chunpu LI, Yechun XU, Haitao YANG, Leike ZHANG, Haixia SU, Hualiang JIANG, Zhenming JIN, Gengfu XIAO, Kaixian CHEN
  • Publication number: 20230133600
    Abstract: A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and/or human cathepsin L inhibitor, and/or may be used in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.
    Type: Application
    Filed: January 28, 2021
    Publication date: May 4, 2023
    Inventors: Hong LIU, Jian LI, Jingjing PENG, Xiong XIE, Wenhao DAI, Shulei HU, Chunpu LI, Leike ZHANG, Zhenming JIN, Yechun XU, Gengfu XIAO, Haitao YANG, Fang BAI, Xi CHENG, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20230077704
    Abstract: Nitazoxanide represented by formula I and an active form thereof, tizoxanide compound, represented by formula II, a geometric isomer thereof and pharmaceutically acceptable salt thereof and/or solvate thereof and/or hydrate thereof, and a pharmaceutical composition containing this compound, used for preventing and/or treating coronavirus (such as SARS-CoV-2) infection.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 16, 2023
    Inventors: Wu Zhong, Gengfu Xiao, Zhihong Hu, Manli Wang, Ruiyan Cao, Leike Zhang, Wei Li, Yuexiang Li, Lei Zhao, Song Li
  • Publication number: 20230071014
    Abstract: A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 9, 2023
    Inventors: Wu Zhong, Zhihong Hu, Gengfu Xiao, Ruiyuan Cao, Manli Wang, Leike Zhang, Wei Li, Shiyong Fan, Song Li
  • Patent number: 11318135
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: May 3, 2022
    Assignee: Academy of Military Medical Sciences
    Inventors: Wu Zhong, Ruiyuan Cao, Cheng Cao, Ting Gao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Song Li
  • Publication number: 20210346411
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Wei LI, Yuexiang LI, Lei ZHAO, Shiyong FAN, Song LI
  • Publication number: 20210346376
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Cheng CAO, Ting GAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Song LI
  • Publication number: 20210220353
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Cheng CAO, Ting GAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Song LI
  • Publication number: 20210220377
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan Cao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Wei Li, Yuexiang Li, Lei Zhao, Shiyong Fan, Song Li